Squarepoint Ops LLC Has $444,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Squarepoint Ops LLC trimmed its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 52.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,168 shares of the biopharmaceutical company's stock after selling 51,783 shares during the quarter. Squarepoint Ops LLC owned 0.10% of Theravance Biopharma worth $444,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock valued at $8,121,000 after buying an additional 4,823 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Theravance Biopharma by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company's stock valued at $610,000 after acquiring an additional 9,315 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Theravance Biopharma during the 4th quarter valued at approximately $119,000. Deutsche Bank AG increased its position in Theravance Biopharma by 50.4% during the 4th quarter. Deutsche Bank AG now owns 46,550 shares of the biopharmaceutical company's stock valued at $438,000 after purchasing an additional 15,608 shares during the period. Finally, Invesco Ltd. raised its holdings in Theravance Biopharma by 3.5% during the 4th quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock worth $433,000 after purchasing an additional 1,576 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

TBPH has been the topic of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $11.33.

Theravance Biopharma Trading Up 4.5%

NASDAQ TBPH traded up $0.48 during trading hours on Friday, hitting $11.25. 295,003 shares of the company's stock were exchanged, compared to its average volume of 276,302. The stock has a 50-day simple moving average of $9.35 and a 200 day simple moving average of $9.39. The firm has a market cap of $562.51 million, a price-to-earnings ratio of -11.14 and a beta of -0.09. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The company had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, sell-side analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.